Literature DB >> 9256160

Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.

B van Triest1, H M Pinedo, F Telleman, C L van der Wilt, G Jansen, G J Peters.   

Abstract

Resistance to some (lipophilic) antifolates has been associated with P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). A possible relationship with non-P-gp MDR has not been established. We studied resistance to antifolates in SW-1573 human lung carcinoma cells, a P-gp overexpressing variant SW-1573/2R160 and a multidrug resistance protein (MRP) overexpressing variant SW-1573/2R120. In this study, thymidylate synthase (TS) inhibitors with different properties concerning the efficiency of membrane transport and the efficiency of polyglutamylation were tested for cross-resistance in SW-1573/2R120 and SW-1573/2R160 cells. Growth inhibition patterns in this cell line panel were measured by the Sulforhodamine B (SRB) assay. Resistance factors for TS inhibitors were: 2.4 and 0.4 for 5-fluorouracil (5FU), 18.8 and 8.8 for ZD1694, 17 and 0.7 for AG337, and 40 and 8.3 for BW1843U89 in SW-1573/2R160 and SW-1573/2R120, respectively. This study showed changes in the TS enzyme kinetics during the induction of doxorubicin resistance in both SW-1573 variants, resulting in 2-fold lower Km values for 2'-deoxyuridine-5'-monophosphate (dUMP) in both resistant variants compared to the parental cell line. TS activity, TS protein induction and TS mRNA expression all had 2-fold increased in the SW-1573/2R120 compared to the SW-1573/2R160. 3H-MTX influx was 2-fold lower in SW-1573/2R160 cells compared to SW-1573/2R120 and SW-1573 cells. In the SW-1573/2R160 cell line, an aberrant intracellular trafficking towards the target TS was observed, compared to SW-1573/2R120 and SW-1573 cells as measured by the TS in situ assay. The rate of TS inhibition by the TS inhibitors used in this study was similar in all cell lines. In conclusion, collateral sensitivity to 5FU and the lipophilic AG337 and cross-resistance to other antifolates were observed in non-P-gp MDR SW-1573/2R120 cells, as well as resistance to all antifolates in P-gp SW-1573/2R160 cells. The mechanism of resistance in SW-1573/2R160 cells possibly involves reduced influx and changes in intracellular trafficking routes. For the SW-1573/2R120 cell line, several changes related to the TS enzyme possibly play a role in the observed cross-resistance and collateral sensitivity pattern.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256160     DOI: 10.1016/s0006-2952(97)82448-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Adenovirus-delivered PDCD5 counteracts adriamycin resistance of osteosarcoma cells through enhancing apoptosis and inhibiting Pgp.

Authors:  Hui Zhao; Changliang Peng; Guorui Ruan; Junlin Zhou; Yihan Li; Yong Hai
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Identification of thymidylate synthase as a potential therapeutic target for lung cancer.

Authors:  K Takezawa; I Okamoto; S Tsukioka; J Uchida; M Kiniwa; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 3.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

4.  Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.

Authors:  Hui Zhao; Wei Guo; Changliang Peng; Tao Ji; Xinchang Lu
Journal:  Mol Biol Rep       Date:  2009-08-22       Impact factor: 2.316

Review 5.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

6.  Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.

Authors:  Irene V Bijnsdorp; Reto A Schwendener; Herbert Schott; Iduna Fichtner; Kees Smid; Adrie C Laan; Sarah Schott; Nienke Losekoot; Richard J Honeywell; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2009-12-03       Impact factor: 3.850

7.  LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.

Authors:  Benny Zhitomirsky; Hodaya Farber; Yehuda G Assaraf
Journal:  J Cell Mol Med       Date:  2018-01-26       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.